CoChat

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Open access
Solini, Anna, Tricò, Domenico, Del Prato, Stefano · 2023 · Diabetologia

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Abstract

Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide cardioprotective benefits through glycaemic and non-glycaemic effects, including improved insulin secretion and action, body-weight loss, blood-pressure lowering and improved lipid profile, as well as via direct effects on the heart and vasculature. These actions are likely combined with anti-inflammatory and antioxidant properties that translate into robust and consistent reductions in atherothrombotic events, particularly in people with type 2 diabetes and established atherosclerotic CVD. GLP-1RAs may also have an impact on obesity and chronic kidney disease, conditions for which cardiovascular risk-reducing options are limited. The available evidence has prompted professional and medical societies to recommend GLP-1RAs for mitigation of the cardiovascular risk in people with type 2 diabetes. This review summarises the clinical evidence for cardiovascular protection with use of GLP-1RAs and the main mechanisms underlying this effect. Moreover, it looks into how the availability of upcoming dual and triple incretin receptor agonists might expand the possibility for cardiovascular protection in people with type 2 diabetes. Graphical Abstract

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-023-05973-w

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Proposed direct mechanisms of cardiovascular protection exerted by pharmacological activation of GLP-1, GIP and glucagon receptors. This figure is available as part of a downloadable slideset
Fig. 1 Proposed direct mechanisms of cardiovascular protection exerted by pharmacological activation of GLP-1, GIP and glucagon receptors. This figure is available as part of a downloadable slidesetCC BY · PubMed Central
Fig. 2 Cardiovascular outcomes and all-cause mortality for GLP-1RAs. Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the meta-analysis by Sattar et al [26], which included all available data from GLP-1RA CVOTs except for FREEDOM CVO. 3P-MACE consisted of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. Data for myocardial infarction and stroke are for both fatal and non-fatal events. Data are plotted on a logarithmic scale (log10). This figure is available as part of a downloadable slideset
Fig. 2 Cardiovascular outcomes and all-cause mortality for GLP-1RAs. Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the meta-analysis by Sattar et al [26], which included all available data from GLP-1RA CVOTs except for FREEDOM CVO. 3P-MACE consisted of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. Data for myocardial infarction and stroke are for both fatal and non-fatal events. Data are plotted on a logarithmic scale (log10). This figure is available as part of a downloadable slidesetCC BY · PubMed Central
Fig. 3 Generalisability of results from GLP-1RA CVOTs to the real-world type 2 diabetes population. The infographic shows the proportion of individuals in the general adult type 2 diabetes population from Spain [30], the UK [31], and the USA [32] that would have been eligible for enrolment in the LEADER [17], SUSTAIN-6 [18] and REWIND [25] trials (sorted by publication date) according to the trials’ key selection criteria. General population with type 2 diabetes, grey; eligible individuals for study enrolment, blue. T2D, type 2 diabetes. This figure is available as part of a downloadable slideset
Fig. 3 Generalisability of results from GLP-1RA CVOTs to the real-world type 2 diabetes population. The infographic shows the proportion of individuals in the general adult type 2 diabetes population from Spain [30], the UK [31], and the USA [32] that would have been eligible for enrolment in the LEADER [17], SUSTAIN-6 [18] and REWIND [25] trials (sorted by publication date) according to the trials’ key selection criteria. General population with type 2 diabetes, grey; eligible individuals for study enrolment, blue. T2D, type 2 diabetes. This figure is available as part of a downloadable slidesetCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 97 references

Cited by

See all 34

Metadata

Authors
Solini, A., Tricò, D., & Del Prato, S.
Affiliations
University of Pisa (IT)
Venue
Diabetologia
Published
2023-08-05
Volume
66
Issue
10
Pages
1820-1831
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4385609776
Cited by
32
References
97
Citations by year
2026: 8 · 2025: 14 · 2024: 9 · 2023: 1
FWCI
1.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Funders
Università di Pisa
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, incretins, cardioprotection, type 2 diabetes, atherosclerotic cardiovascular disease, cardioprotection mechanisms, insulin secretion, blood pressure, lipid profile, obesity, chronic kidney disease, antioxidant and anti-inflammatory effects
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incretins and cardiovascular disease: to the heart of type 2 diabetes? https://app.cochat.ai/papers/10.1007/s00125-023-05973-w
The paper
Solini, A., Tricò, D., & Del Prato, S. (2023). Incretins and cardiovascular disease: to the heart of type 2 diabetes? Diabetologia. https://doi.org/10.1007/s00125-023-05973-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.